Contributing to the promise of Surgical Oncology
17 March 2017
Researchers and clinicians from Melanoma Institute Australia (MIA) are meeting with more than 1,700 colleagues from around the world today at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium in Seattle, USA. The theme of the meeting is “discovering the promise of what’s possible” and invites attendees to learn about the exciting possibilities for improving oncologic outcomes for patients.
The conference provides surgical oncology leaders with an opportunity to share research and network to advance the field. Four of MIA’s current or former fellows are presenting their research to colleagues at the conference, in addition to several more in attendance.
MIA's 2016 Poche Surgical Fellow, Dr Kim Isaacs, is sharing her research at the conference. Most guidelines recommend that melanoma patients have a complete lymph node dissection after they have had a positive sentinel lymph node identified; however, this doesn’t always happen. Dr Isaacs’s research investigated the factors that influence a melanoma patient’s choice to have a complete lymph node dissection or not. This research will help determine why some patients are not going ahead with this potentially life-saving surgery.
Research fellow, Trine Schoenfeldt, from Denmark is presenting her MIA research that is looking at the ideal surgical management for patients who have melanoma metastases in the sentinel nodes located near their armpit (specifically the triangular intermuscular space). How to manage patients with these metastases is considered controversial for surgeons, so having scientific evidence about the best course of treatment will ensure the best care for patients.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.